Does Aspirin Prevent Incident Heart Failure in Healthy Older Adults? Examining the Evidence From the ASPREE Trial

TY - JOUR

T1 - Does Aspirin Prevent Incident Heart Failure in Healthy Older Adults? Examining the Evidence From the ASPREE Trial

AU - Zhou, Zhen

AU - Nelson, Mark

AU - Ernst, Michael E.

AU - Reid, Christopher

AU - McNeil, John

AU - Tonkin, Andrew

N1 - Funding Information: The ASPREE trial (Aspirin in Reducing Events in the Elderly) was supported by grants from the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (U01AG029824), the National Health and Medical Research Council of Australia, and Monash University and the Victorian Cancer Agency (334047, 112706). Funding Information: Dr Tonkin reported receiving research support or honoraria from Amgen, Boehringer- Ingelheim, Merck, and Pfizer, as well as materials in the ASPREE trial (Aspirin in Reducing Events in the Elderly) from Bayer. Dr Nelson reported receiving honoraria from Sanofi and Amgen, as well as Bayer for materials in ASPREE. Dr Reid reported being funded through a National Health and Medical Research Council Principal Research Fellowship. The other authors report no conflicts.

PY - 2022/6/1

Y1 - 2022/6/1

KW - aged

KW - aspirin

KW - coronary artery disease

KW - diagnosis

KW - heart failure

KW - primary prevention

UR - http://www.scopus.com/inward/record.url?scp=85132254419&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.122.009511

DO - 10.1161/CIRCHEARTFAILURE.122.009511

M3 - Letter

C2 - 35727884

AN - SCOPUS:85132254419

SN - 1941-3289

VL - 15

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

IS - 6

M1 - E009511

ER -